SCHEMBL7540401

SCHEMBL7540401

CNc1ccc(NS(=O)(=O)c2ccc(Cl)c(C#N)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 8/20 0.54
ACLY P53396 2/20 0.51
PLA2G7 Q13093 2/20 0.50
BRD4 O60885 1/20 0.48
BRD1 O95696 1/20 0.48
BRPF1 P55201 1/20 0.48
BRD9 Q9H8M2 1/20 0.48
BRPF3 Q9ULD4 1/20 0.48
MAPT P10636 4/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
CES1 P23141 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678633 0.85 ALDH1A1 (0.60) SLC22A12ACLYPLA2G7BRD4BRD1
SCHEMBL6674281 0.85 MAPT (0.61) SLC22A12PLA2G7MAPTNPSR1ALDH1A1
SCHEMBL6678890 0.81 LMNA (0.67) SLC22A12PLA2G7MAPTNPSR1MEN1
SCHEMBL6677842 0.78 LMNA (0.64) SLC22A12ACLYPLA2G7MAPTNPSR1
SCHEMBL6681275 0.78 PLA2G7 (0.56) SLC22A12PLA2G7MAPTNPSR1MEN1
SCHEMBL8343255 0.77 SLC22A12 (0.50) SLC22A12PLA2G7MAPTALDH1A1
SCHEMBL28047475 0.75 ALDH1A1 (0.63) MAPTMEN1HTTKMT2ACES1
SCHEMBL4195364 0.74 EPAS1 (0.51) SLC22A12ACLYMAPTALDH1A1LMNA
SCHEMBL15867027 0.73 VCAM1 (0.53) SLC22A12ACLYPLA2G7MEN1CYP3A4
SCHEMBL6675727 0.72 ALDH1A1 (0.57) SLC22A12ACLYMAPTNPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 SLC22A12 3172/4885ACLY 2752/4885PLA2G7 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.